Ingenol Mebutate Is Associated With Increased Reporting Odds for SCC in Patients With Actinic Keratosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Cutaneous Medicine and Surgery
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
J Cutan Med Surg 2022 Dec 10;[EPub Ahead of Print], PM JedlowskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.